The system was used for treatment.This case is reportable as a mdr due to the reportable malfunction clot observed in the return line.Since this reportable malfunction is only associated with the kit, this mdr will only be against the kit.A batch record review for kit lot g374 was conducted.There were no non-conformances associated with this lot.This lot met all release requirements.A review of kit lot g374 for the reported issue shows no trends.Trends were reviewed for complaint categories, clot observed and alarm #17: return pressure.No trends were detected for each complaint category.Photographs were provided by the customer for evaluation.The smartcard was not returned; therefore, the alarm #17: return pressure could not be verified.A review of the photographs confirm clotting in the return bag as reported by the customer.The customer reported seeing a clot in the return line, however the photographs provided do not show the return line and therefore clotting in that location cannot be verified.The customer reported using 10,000 units of heparin in 500ml of normal saline, the default anticoagulant (a/c) ratio for the cellex photopheresis system.Section 2-9 of the cellex operators manual (1460415 rev 5.0) on anticoagulant states "caution: individual patients may require a heparin dosage that varies from the recommended dose to prevent post-treatment bleeding or clotting during a treatment.The physician should review the patient's medical condition, medications and platelet count at the time of treatment and use clinical judgement to establish the optimal heparin dosage for each patient." the root cause for the clot observed could not be determined based on the available information.No further action is required at this time.This investigation is now complete.(b)(4).
|